Tampouratzi, Eleftheria, Georgiadis, Manos, Cheliotis, George, Pesiridis, George, Dikeakos, Panagiotis, Kostaki, Maria, Karkalousos, Petros, Katsantonis, John and Sfaelos, Konstantinos (2023) Psoriasis, physical activity and Brodalumab treatment. World journal of Pharmaceutical Science and Research, 2 (5). pp. 1-7. ISSN 2583-6579

Preview

Text Psoriasis physical activity and Brodalumab treatment.pdf - Published Version Available under License Creative Commons Attribution Non-commercial No Derivatives. Download (799kB) | Preview

Abstract

Purpose: The Environmental and genetic factors seem to have a crucial role in the psoriasis treatment. The objective is to investigate the improvement and fast response of moderate-to-severe psoriasis under brodalumab treatment, in patients who exercise more intensely compared to those with reduced physical activity. Design/Setting: Patients divided into 3 groups depending on their physical activity intensity (high-moderate-low) by International Physical Activity Questionnaire (IPAQ). Subjects: Adult, moderate-to-severe plaque psoriasis patients treated with brodalumab were involved. Measures: Psoriasis was evaluated with Psoriasis Area Severity Index (PASI), quality of life was estimated with Dermatology Life Quality Index (DLQI) and inflammation was measured with C-Reactive Protein (CRP) at 0, 12 and 52 weeks. Results: At baseline, patients (N=40) had mean age 51 years and mean PASI [Standard Deviation-(SD)] score 20.35 (6.16). The relevant results were: mean (SD) PASI score: 1.67 (1.21), p-value<0.001; mean (SD) DLQI scores: baseline, 15.72 (5.25); week 52, 0.47 (1.41), pvalue<0.001; mean (SD) CRP values: baseline, 3.03 (2.82); week 52, 1.86 (1.84), p-value=0.003; mean overall physical activity (SD): baseline, 1237.59 min/week (1780.43); week 52, 2046.19 min/week (2006.93), pvalue<0.001. Conclusions: The statistically significant results confirm the initial aim of the study, indicating that the rapid improvement and maintenance of the outcome in the long-term treatment with brodalumab is enhanced in patients with increased physical activity. The real-world treatment effectiveness and physical activity relation, alongside the pathophysiological mechanism of the potential physical activity impact on the therapeutic outcome, is an interesting field to be further explored.

Actions (login required)

View Item